Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis

C. Rajda, J. Bergquist, L. Vécsei

Research output: Chapter in Book/Report/Conference proceedingChapter

15 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is a chronic, demyelinating disease of unknown origin. Sophisticated analytical methods have made it possible to measure small biologically active molecules at low endogenous levels, and understand their role in the network of other biologically active compounds actively involved in inflammatory and neurodegenerative processes. Evidence is accumulating as concerns the disturbances of the kynurenine pathway and redox changes in MS. A new promising metabolite of the kynurenine pathway seems to beneficially influence experimental allergic encephalomyelitis. More clinical evidence is needed to prove the role of kynurenic acid analogues and/or enzyme inhibitors as potential medications in MS in the future. Various compounds have been shown to be important in the pathophysiological processes of the disease and are targets for pharmaceutical intervention.

Original languageEnglish
Title of host publicationJournal of Neural Transmission, Supplementa
Pages323-329
Number of pages7
Edition72
DOIs
Publication statusPublished - 2007

Publication series

NameJournal of Neural Transmission, Supplementa
Number72
ISSN (Print)03036995

Fingerprint

Kynurenine
Multiple Sclerosis
Oxidation-Reduction
Kynurenic Acid
Autoimmune Experimental Encephalomyelitis
Demyelinating Diseases
Enzyme Inhibitors
Chronic Disease
Pharmaceutical Preparations

Keywords

  • Antioxidants
  • experimental allergic encephalomyelitis
  • kynurenic acid
  • kynurenine
  • multiple sclerosis
  • redox disturbance

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Rajda, C., Bergquist, J., & Vécsei, L. (2007). Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis. In Journal of Neural Transmission, Supplementa (72 ed., pp. 323-329). (Journal of Neural Transmission, Supplementa; No. 72). https://doi.org/10.1007/978-3-211-73574-9-40

Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis. / Rajda, C.; Bergquist, J.; Vécsei, L.

Journal of Neural Transmission, Supplementa. 72. ed. 2007. p. 323-329 (Journal of Neural Transmission, Supplementa; No. 72).

Research output: Chapter in Book/Report/Conference proceedingChapter

Rajda, C, Bergquist, J & Vécsei, L 2007, Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis. in Journal of Neural Transmission, Supplementa. 72 edn, Journal of Neural Transmission, Supplementa, no. 72, pp. 323-329. https://doi.org/10.1007/978-3-211-73574-9-40
Rajda C, Bergquist J, Vécsei L. Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis. In Journal of Neural Transmission, Supplementa. 72 ed. 2007. p. 323-329. (Journal of Neural Transmission, Supplementa; 72). https://doi.org/10.1007/978-3-211-73574-9-40
Rajda, C. ; Bergquist, J. ; Vécsei, L. / Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis. Journal of Neural Transmission, Supplementa. 72. ed. 2007. pp. 323-329 (Journal of Neural Transmission, Supplementa; 72).
@inbook{268702f56dd141b5820975ea21f5e03d,
title = "Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis",
abstract = "Multiple sclerosis (MS) is a chronic, demyelinating disease of unknown origin. Sophisticated analytical methods have made it possible to measure small biologically active molecules at low endogenous levels, and understand their role in the network of other biologically active compounds actively involved in inflammatory and neurodegenerative processes. Evidence is accumulating as concerns the disturbances of the kynurenine pathway and redox changes in MS. A new promising metabolite of the kynurenine pathway seems to beneficially influence experimental allergic encephalomyelitis. More clinical evidence is needed to prove the role of kynurenic acid analogues and/or enzyme inhibitors as potential medications in MS in the future. Various compounds have been shown to be important in the pathophysiological processes of the disease and are targets for pharmaceutical intervention.",
keywords = "Antioxidants, experimental allergic encephalomyelitis, kynurenic acid, kynurenine, multiple sclerosis, redox disturbance",
author = "C. Rajda and J. Bergquist and L. V{\'e}csei",
year = "2007",
doi = "10.1007/978-3-211-73574-9-40",
language = "English",
isbn = "9783211735732",
series = "Journal of Neural Transmission, Supplementa",
number = "72",
pages = "323--329",
booktitle = "Journal of Neural Transmission, Supplementa",
edition = "72",

}

TY - CHAP

T1 - Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis

AU - Rajda, C.

AU - Bergquist, J.

AU - Vécsei, L.

PY - 2007

Y1 - 2007

N2 - Multiple sclerosis (MS) is a chronic, demyelinating disease of unknown origin. Sophisticated analytical methods have made it possible to measure small biologically active molecules at low endogenous levels, and understand their role in the network of other biologically active compounds actively involved in inflammatory and neurodegenerative processes. Evidence is accumulating as concerns the disturbances of the kynurenine pathway and redox changes in MS. A new promising metabolite of the kynurenine pathway seems to beneficially influence experimental allergic encephalomyelitis. More clinical evidence is needed to prove the role of kynurenic acid analogues and/or enzyme inhibitors as potential medications in MS in the future. Various compounds have been shown to be important in the pathophysiological processes of the disease and are targets for pharmaceutical intervention.

AB - Multiple sclerosis (MS) is a chronic, demyelinating disease of unknown origin. Sophisticated analytical methods have made it possible to measure small biologically active molecules at low endogenous levels, and understand their role in the network of other biologically active compounds actively involved in inflammatory and neurodegenerative processes. Evidence is accumulating as concerns the disturbances of the kynurenine pathway and redox changes in MS. A new promising metabolite of the kynurenine pathway seems to beneficially influence experimental allergic encephalomyelitis. More clinical evidence is needed to prove the role of kynurenic acid analogues and/or enzyme inhibitors as potential medications in MS in the future. Various compounds have been shown to be important in the pathophysiological processes of the disease and are targets for pharmaceutical intervention.

KW - Antioxidants

KW - experimental allergic encephalomyelitis

KW - kynurenic acid

KW - kynurenine

KW - multiple sclerosis

KW - redox disturbance

UR - http://www.scopus.com/inward/record.url?scp=38449098312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449098312&partnerID=8YFLogxK

U2 - 10.1007/978-3-211-73574-9-40

DO - 10.1007/978-3-211-73574-9-40

M3 - Chapter

C2 - 17982910

AN - SCOPUS:38449098312

SN - 9783211735732

T3 - Journal of Neural Transmission, Supplementa

SP - 323

EP - 329

BT - Journal of Neural Transmission, Supplementa

ER -